{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-018635","form_type":"8-K","ticker":"LQDA","cik":"0001819576","company_name":"Liquidia Corp","filed_at":"2025-02-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:05.053335+00:00","generated_at":"2026-05-25T23:53:49.559470+00:00","sec_items":["8.01","9.01"],"event_type":"litigation","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Liquidia loses court challenge to FDA's Tyvaso DPI exclusivity; cross claim still pending","bullets":["On Feb 27, 2025, District Court denied Liquidia's summary judgment motion, affirming FDA's 3-year exclusivity for Tyvaso DPI.","Exclusivity expiration remains May 23, 2025; decision does not change that date.","United Therapeutics' cross claim challenging FDA's acceptance of Liquidia's amended NDA remains pending; dismissal motions not yet ruled on.","Liquidia filed lawsuit in August 2024; this ruling is a legal setback for their NDA approval timeline."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-018635","json":"https://secwatch.observer/filing/0001104659-25-018635.json","markdown":"https://secwatch.observer/filing/0001104659-25-018635.md","text":"https://secwatch.observer/filing/0001104659-25-018635.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1819576/000110465925018635/0001104659-25-018635-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1819576/000110465925018635/tm257909d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-25T23:53:49.559470+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}